XASXEMD
Market cap10mUSD
Jan 08, Last price
0.03AUD
1D
-2.78%
1Q
12.90%
IPO
-73.08%
Name
Emyria Ltd
Chart & Performance
P/E
—
P/S
7.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.94%
Rev. gr., 5y
82.13%
Revenues
2m
+38.32%
Net income
-11m
L+123.26%
CFO
-4m
L+13.61%
Earnings
Feb 26, 2025
Profile
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and irritable bowel syndrome; and EMD-RX7 for multiple medical conditions. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | |
| Income | |||||||
Revenues | 2,203 38.32% | 1,592 -12.62% | 1,822 -7.77% | ||||
Cost of revenue | 6,466 | 8,710 | 10,361 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (4,263) | (7,118) | (8,538) | ||||
NOPBT Margin | |||||||
Operating Taxes | (2,527) | (2,090) | (1,162) | ||||
Tax Rate | |||||||
NOPAT | (1,736) | (5,028) | (7,376) | ||||
Net income | (11,456) 123.26% | (5,131) -29.98% | (7,328) 49.35% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 5,019 | 4,860 | 4,512 | ||||
BB yield | |||||||
| Debt | |||||||
Debt current | 1,031 | 1,131 | 269 | ||||
Long-term debt | 1,592 | 280 | 728 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 72 | 81 | 107 | ||||
Net debt | 1,057 | (1,467) | (3,044) | ||||
| Cash flow | |||||||
Cash from operating activities | (4,285) | (3,772) | (5,428) | ||||
CAPEX | (159) | (3,234) | (2,029) | ||||
Cash from investing activities | (1,378) | (3,234) | (2,029) | ||||
Cash from financing activities | 4,495 | 5,859 | 4,808 | ||||
FCF | (2,504) | (4,448) | (7,172) | ||||
| Balance | |||||||
Cash | 1,566 | 2,734 | 3,879 | ||||
Long term investments | 145 | 161 | |||||
Excess cash | 1,456 | 2,798 | 3,950 | ||||
Stockholders' equity | 2,425 | 6,794 | 6,322 | ||||
Invested Capital | 2,760 | 5,347 | 3,112 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 358,969 | 289,387 | 268,612 | ||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | (3,568) | (6,717) | (8,148) | ||||
EV/EBITDA | |||||||
Interest | 253 | 129 | 72 | ||||
Interest/NOPBT | |||||||